Lilly’s Retevmo boosts event-free survival in early-stage NSCLC

Eli Lilly’s oral targeted cancer therapy, Retevmo, has shown benefit as an adjunctive therapy in a Phase III trial in ...

Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 LIBRETTO-432 clinical trial of ...
The Pharma Letter

Lilly's Retevmo delivers substantial event-free survival benefit

US pharma major Eli Lilly today announced positive top-line results from the Phase III LIBRETTO-432 clinical trial of Retevmo ...

Eli Lilly Reports Phase 3 Win for Retevmo in Early Lung Cancer

LIBRETTO-432 shows statistically significant event-free survival benefit in RET fusion-positive NSCLC after initial therapy.
Morningstar

Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with ...

The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study These data will be simultaneously published in the Journal ...
Pharmabiz

Lilly's phase 3 LIBRETTO-432 trial of Retevmo an adjuvant therapy in early-stage RET fusion-positive lung cancer meets its primary endpoint

Lilly's phase 3 LIBRETTO-432 trial of Retevmo an adjuvant therapy in early-stage RET fusion-positive lung cancer meets its primary endpoint: Indianapolis Tuesday, February 17, 202 ...
Seeking Alpha

Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with ...

Entering text into the input field will update the search result below Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by ...